What are Mike Doukeris's latest trade ideas?

Buzzberg tracks 1 AI-analyzed trade ideas from Mike Doukeris. View bullish and bearish calls with confidence scores.

What is Mike Doukeris's track record on Buzzberg?

Mike Doukeris has 1 AI-analyzed trade ideas tracked on Buzzberg with a credibility score of 1.7. Coverage includes HIMS and other tickers.

Mike Doukeris 1.7 1 idea

CEO, Anheuser-Busch InBev

After 1 day

N/A

1/15 min ideas

After 1 week

N/A

1/15 min ideas

After 1 month

N/A

1/15 min ideas

0 winning / 1 losing · 1 positions (30d)

Net: -48.4%

By sector

Stock

1 ideas -48.4%

Top tickers (by frequency)

HIMS 1 ideas

0% W -48.4%

Best and worst calls

Best calls

HIMS SHORT -48.4%

Novo Nordisk has filed lawsuits against Hims & Hers (and others) for patent infringement regarding compounded GLP-1s. If...

Feb 11

Worst calls

HIMS SHORT -48.4%

Novo Nordisk has filed lawsuits against Hims & Hers (and others) for patent infringement regarding compounded GLP-1s. If...

Feb 11

▶ YouTube Stocks Steady After Strong Jobs Data Dims Rate-Cut Bets | The Close 2/11/2026

Novo Nordisk has filed lawsuits against Hims & Hers (and others) for patent infringement regarding compounded GLP-1s. If NVO successfully blocks the sale of compounded semaglutide, HIMS loses a massive, high-margin revenue stream that has driven its recent growth. SHORT. Regulatory and legal headwinds are mounting against the "mass compounding" business model. Lawsuits could drag on for years; FDA could maintain shortage list status allowing compounding to continue.

HIMS Bloomberg Markets Feb 11, 23:55

Mike Doukeris

CEO, Novo Nordisk